Found: 54
Select item for more details and to access through your institution.
Use of SuperARMS EGFR Mutation Detection Kit to Detect EGFR in Plasma Cell-free DNA of Patients With Lung Adenocarcinoma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Squamous Cell Lung Cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.1001503
- By:
- Publication type:
- Article
On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1173025
- By:
- Publication type:
- Article
Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer.
- Published in:
- Frontiers in Immunology, 2023, v. 13, p. 1, doi. 10.3389/fimmu.2023.1094378
- By:
- Publication type:
- Article
Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer.
- Published in:
- Thoracic Cancer, 2024, v. 15, n. 5, p. 419, doi. 10.1111/1759-7714.15209
- By:
- Publication type:
- Article
Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer.
- Published in:
- Thoracic Cancer, 2023, v. 14, n. 34, p. 3421, doi. 10.1111/1759-7714.15157
- By:
- Publication type:
- Article
Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive‐stage small‐cell lung cancer patients (DURABLE study).
- Published in:
- Clinical Respiratory Journal, 2023, v. 17, n. 12, p. 1361, doi. 10.1111/crj.13715
- By:
- Publication type:
- Article
Serum TNFRII: A promising biomarker for predicting the risk of subcentimetre lung adenocarcinoma.
- Published in:
- Journal of Cellular & Molecular Medicine, 2020, v. 24, n. 7, p. 4150, doi. 10.1111/jcmm.15071
- By:
- Publication type:
- Article
Acyloxyacyl hydrolase promotes the resolution of lipopolysaccharide-induced acute lung injury.
- Published in:
- PLoS Pathogens, 2017, v. 13, n. 6, p. 1, doi. 10.1371/journal.ppat.1006436
- By:
- Publication type:
- Article
Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming.
- Published in:
- Advanced Therapeutics, 2023, v. 6, n. 11, p. 1, doi. 10.1002/adtp.202300141
- By:
- Publication type:
- Article
EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study.
- Published in:
- Clinical Lung Cancer, 2021, v. 22, n. 3, p. e395, doi. 10.1016/j.cllc.2020.06.005
- By:
- Publication type:
- Article
hsa_circ_0003222 accelerates stemness and progression of non-small cell lung cancer by sponging miR-527.
- Published in:
- Cell Death & Disease, 2021, v. 12, n. 9, p. 1, doi. 10.1038/s41419-021-04095-8
- By:
- Publication type:
- Article
Comparison of the Clinical Effects of Paclitaxel and Paclitaxel plus Oxaliplatin as the Second-line Treatment of Advanced Non-small Cell Lung Cancer.
- Published in:
- Chinese Journal of Lung Cancer, 2009, v. 12, n. 11, p. 1178, doi. 10.3779/j.issn.1009-3419.2009.11.10
- By:
- Publication type:
- Article
Analysis of Differential Gel Electrophoresis of Paclitaxol Resistant and Sensitive Lung Adenocarcinoma Cells' Secretome.
- Published in:
- Chinese Journal of Lung Cancer, 2009, v. 12, n. 7, p. 735, doi. 10.3779/j.issn.1009-3419.2009.07.001
- By:
- Publication type:
- Article
Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.812555
- By:
- Publication type:
- Article
Does surgically resected small‐cell lung cancer without lymph node involvement benefit from prophylactic cranial irradiation?
- Published in:
- Thoracic Cancer, 2020, v. 11, n. 5, p. 1239, doi. 10.1111/1759-7714.13381
- By:
- Publication type:
- Article
First‐line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non‐squamous non‐small cell lung cancer with wild‐type driver genes: A real‐world study in China
- Published in:
- Thoracic Cancer, 2019, v. 10, n. 5, p. 1043, doi. 10.1111/1759-7714.13025
- By:
- Publication type:
- Article
Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1625, doi. 10.1007/s00262-021-03100-5
- By:
- Publication type:
- Article
Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 01, doi. 10.3389/fimmu.2022.937924
- By:
- Publication type:
- Article
Adjuvant Chemotherapy Candidates in Stage I Lung Adenocarcinomas Following Complete Lobectomy.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2019, v. 26, n. 8, p. 2392, doi. 10.1245/s10434-019-07366-z
- By:
- Publication type:
- Article
Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study.
- Published in:
- BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12479-0
- By:
- Publication type:
- Article
Acyloxyacyl hydrolase promotes pulmonary defense by preventing alveolar macrophage tolerance.
- Published in:
- PLoS Pathogens, 2023, v. 19, n. 7, p. 1, doi. 10.1371/journal.ppat.1011556
- By:
- Publication type:
- Article
Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients.
- Published in:
- Biomarker Research, 2022, v. 10, n. 1, p. 1, doi. 10.1186/s40364-022-00400-5
- By:
- Publication type:
- Article
Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations.
- Published in:
- Frontiers in Oncology, 2024, p. 01, doi. 10.3389/fonc.2024.1357231
- By:
- Publication type:
- Article
Atorvastatin suppressed proliferation and facilitated apoptosis of A549 cells through mediating recruitment of Fas and CD59 in lipid raft.
- Published in:
- Tropical Journal of Pharmaceutical Research, 2022, v. 21, n. 2, p. 237, doi. 10.4314/tjpr.v21i2.4
- By:
- Publication type:
- Article
Circulating DNA‐Based Sequencing Guided Anlotinib Therapy in Non‐Small Cell Lung Cancer.
- Published in:
- Advanced Science, 2019, v. 6, n. 19, p. N.PAG, doi. 10.1002/advs.201900721
- By:
- Publication type:
- Article
Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial.
- Published in:
- Cancer Biology & Medicine, 2021, v. 18, n. 3, p. 816, doi. 10.20892/j.issn.2095-3941.2020.0212
- By:
- Publication type:
- Article
Progress in Detection of EGFR Exon 20 Insertion Mutation and Targeted Therapies in Non-small Cell Lung Cancer.
- Published in:
- Chinese Journal of Lung Cancer, 2023, v. 26, n. 2, p. 135, doi. 10.3779/j.issn.1009-3419.2023.102.06
- By:
- Publication type:
- Article
Decreased green autofluorescence of lung parenchyma is a biomarker for lung cancer tissues.
- Published in:
- Journal of Biophotonics, 2022, v. 15, n. 8, p. 1, doi. 10.1002/jbio.202200072
- By:
- Publication type:
- Article
Inside Cover.
- Published in:
- Journal of Biophotonics, 2022, v. 15, n. 5, p. 1, doi. 10.1002/jbio.202270012
- By:
- Publication type:
- Article
Skin's green autofluorescence at dorsal centremetacarpus may become a novel biomarker for diagnosis of lung cancer.
- Published in:
- Journal of Biophotonics, 2022, v. 15, n. 5, p. 1, doi. 10.1002/jbio.202100389
- By:
- Publication type:
- Article
Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer.
- Published in:
- Journal of Oncology, 2020, p. 1, doi. 10.1155/2020/8811487
- By:
- Publication type:
- Article
The prognosis and metabolite changes of NSCLC patients receiving first‐line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classification.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 17, p. 1, doi. 10.1002/cam4.70223
- By:
- Publication type:
- Article
Mining GEO and TCGA Database for Immune Microenvironment of Lung Squamous Cell Carcinoma Patients With or Without Chemotherapy.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.835225
- By:
- Publication type:
- Article
Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.652560
- By:
- Publication type:
- Article
Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.
- Published in:
- Yonsei Medical Journal, 2017, v. 58, n. 3, p. 581, doi. 10.3349/ymj.2017.58.3.581
- By:
- Publication type:
- Article
Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 4, p. 1417, doi. 10.1007/s00432-022-03964-9
- By:
- Publication type:
- Article
New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2020, v. 146, n. 3, p. 631, doi. 10.1007/s00432-020-03129-6
- By:
- Publication type:
- Article
Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2020, v. 146, n. 2, p. 401, doi. 10.1007/s00432-019-03064-1
- By:
- Publication type:
- Article
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2016, v. 142, n. 6, p. 1325, doi. 10.1007/s00432-016-2133-4
- By:
- Publication type:
- Article
Lentivirus-mediated knockdown of CTDP1 inhibits lung cancer cell growth in vitro.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2016, v. 142, n. 4, p. 723, doi. 10.1007/s00432-015-2070-7
- By:
- Publication type:
- Article
Dynamic alterations of ctDNA associate with the therapeutic outcome in the advanced non‐small cell lung cancer patients who received sintilimab plus anlotinib regime as 1st line therapy.
- Published in:
- Clinical & Translational Medicine, 2023, v. 13, n. 6, p. 1, doi. 10.1002/ctm2.1277
- By:
- Publication type:
- Article
Clinical Features and Outcomes Analysis of Surgical Resected Pulmonary Large-Cell Neuroendocrine Carcinoma With Adjuvant Chemotherapy.
- Published in:
- Frontiers in Oncology, 2020, v. 11, p. N.PAG, doi. 10.3389/fonc.2020.556194
- By:
- Publication type:
- Article
CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients.
- Published in:
- Frontiers in Oncology, 2020, p. 1, doi. 10.3389/fonc.2020.01049
- By:
- Publication type:
- Article
EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 2, p. 277, doi. 10.1007/s11523-024-01042-3
- By:
- Publication type:
- Article
Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study).
- Published in:
- 2022
- By:
- Publication type:
- journal article